Acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans: A TD-fNIRS neuroimaging study

Adelaida Castillo, Julien Dubois, Ryan M. Field, Frank A. Fishburn, Andrew Gundran, Wilson C. Ho, Sami Jawhar, Julian Kates‐Harbeck, Zahra M. Aghajan, Naomi Miller, Katherine L. Perdue, Jake Phillips, Wesley C. Ryan, Mahdi Shafiei, Felix Scholkmann, Moriah TaylorbioRxiv 2023 · DOI

TL;DR

This study successfully uses a novel whole-head TD-fNIRS system to measure acute cerebrovascular and physiological changes in healthy individuals after subanesthetic ketamine administration. The findings demonstrate ketamine's impact on brain activity (reduced fALFF) and connectivity (decreased prefrontal GBC), alongside systemic physiological changes, paving the way for fNIRS in clinical psychedelic research.

What Problem Does This Paper Address?

Understanding the acute effects of psychoactive substances like ketamine on the brain is crucial for developing effective treatments for conditions like depression. While fMRI has been used, it's expensive and not easily deployable in clinical settings. Previous studies using fNIRS have been limited in scope or technical sophistication. This paper addresses the need for a scalable, clinically relevant neuroimaging technique to investigate ketamine's immediate physiological and neural impacts, aiming to uncover potential biomarkers for treatment response and understand its mechanisms of action. The authors highlight the difficulty in achieving consensus in existing neuroimaging studies due to small sample sizes and methodological variations, emphasizing the need for robust, standardized approaches.

Methods

The study employed a single-blind, within-subject, placebo-controlled design using a novel whole-head time-domain functional near-infrared spectroscopy (TD-fNIRS) system called Kernel Flow. Participants received either subanesthetic ketamine (0.75 mg/kg) or saline intramuscularly on separate visits. The TD-fNIRS system captured detailed optical data, allowing for the measurement of:

  • Cerebrovascular Hemodynamics: Absolute concentrations of oxyhemoglobin (HbO) and deoxyhemoglobin (HbR) were calculated.
  • Brain Activity: Fractional Amplitude of Low-Frequency Fluctuations (fALFF) was computed as a proxy for local neuronal activity.
  • Functional Connectivity: Global Brain Connectivity (GBC) of the prefrontal cortex was assessed using graph theory metrics.
  • Systemic Physiology: Alongside fNIRS, auxiliary sensors measured pulse rate (PR), heart rate variability (HRV), electrodermal activity (EDA), respiration rate, SpO2, and end-tidal CO2 (EtCO2).

The TD-fNIRS system's ability to capture time-resolved photon data (DTOFs) is a key technical advancement, enabling more precise measurements compared to continuous-wave fNIRS. Data preprocessing involved motion correction and conversion of optical properties to hemoglobin concentrations.

Datasets

The study utilized data collected from 15 healthy participants (8 females, 7 males; age 32.4 ± 7.5 years). No external datasets were used for training or evaluation. The data collected from these participants during the ketamine and saline dosing sessions, along with baseline measurements, served as the sole dataset for analysis.

Key Insights and Ideas

  • TD-fNIRS as a Clinically Viable Tool: The study demonstrates the successful application of a portable, whole-head TD-fNIRS system in a clinical setting, highlighting its potential for future large-scale studies in psychedelic-assisted therapy.
  • Ketamine's Dual Impact: Ketamine not only alters subjective states (mystical experiences, altered consciousness) but also demonstrably affects both systemic physiology (increased pulse rate, elevated EDA) and brain function (reduced fALFF, decreased prefrontal connectivity).
  • Predictive Power of Combined Metrics: Preliminary evidence suggests that a combination of neural (fALFF) and physiological (PR) features can predict subjective mystical experiences, opening avenues for personalized treatment optimization.
  • fALFF as a Potential Biomarker: The observed reduction in fALFF during ketamine administration, particularly in the later stages, aligns with findings in depression research and suggests fALFF could be a biomarker for treatment outcomes, though caution is advised due to the healthy volunteer sample.

Key Results

  • Physiological Changes: Ketamine administration led to a significant increase in pulse rate (82%) and a significant decrease in pulse rate variability (91%) compared to saline. Electrodermal activity (EDA) was also elevated during ketamine sessions.
  • Brain Activity: Whole-brain fALFF showed a marked decrease during ketamine dosing sessions, particularly in the second half, for both HbO and HbR. This reduction was more sustained than the increase in pulse rate.
  • Brain Connectivity: Ketamine acutely reduced global brain connectivity (GBC) of the prefrontal cortex compared to saline. This reduction was significant for HbO and showed a trend for HbR.
  • Predictive Modeling: A model combining time-varying PR and fALFF features could predict participants' mystical experience scores (RMEQ), with an r-squared of 0.24 on the held-out set. The interaction between session type (ketamine vs. saline) and fALFF significantly predicted changes in depressive symptoms (QIDS scores).

Limitations and Future Work

  • Sample Size and Population: The study's small sample size (n=15) and use of healthy volunteers limit the generalizability of findings to clinically depressed populations. Future work should include MDD patients.
  • Single-Blind Design: While participants were blinded to the drug, the potent subjective effects of ketamine may have led to unblinding. Future studies could aim for double-blind designs.
  • Limited Connectivity Analysis: The study focused on global prefrontal connectivity. Future research could explore more detailed network-specific connectivity and employ more sophisticated anatomical modeling.
  • Measurement Limitations: fNIRS has limitations in depth sensitivity and can be influenced by systemic physiology. Combining fNIRS with other modalities like EEG is suggested for a more comprehensive understanding.
  • Future Directions: The authors emphasize the need for larger-scale, longitudinal studies in clinical populations to validate these findings and explore the therapeutic potential of combined neural and physiological biomarkers for tailoring psychedelic-assisted therapies. Further investigation into the time course of subjective experiences and their correlation with neural/physiological measures is also recommended.

Summary updated

Abstract

Abstract Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administration of psychedelics may further our scientific understanding of the effects and mechanisms of action. This data may facilitate the discovery of novel biomarkers enabling more personalized treatments and improved patient outcomes. In this single-blind, placebo-controlled study with a non-randomized design, we use time-domain functional near-infrared spectroscopy (TD-fNIRS) to measure acute brain dynamics after intramuscular subanesthetic ketamine (0.75 mg/kg) and placebo (saline) administration in healthy participants ( n = 15, 8 females, 7 males, age 32.4 ± 7.5 years) in a clinical setting. We found that the ketamine administration caused an altered state of consciousness and changes in systemic physiology (e.g. increase in pulse rate and electrodermal activity). Furthermore, ketamine led to a brain-wide reduction in the fractional amplitude of low frequency fluctuations (fALFF), and a decrease in the global brain connectivity of the prefrontal region. Lastly, we provide preliminary evidence that a combination of neural and physiological metrics may serve as predictors of subjective mystical experiences and reductions in depressive symptomatology. Overall, our studies demonstrated the successful application of fNIRS neuroimaging to study the physiological effects of the psychoactive substance ketamine and can be regarded as an important step toward larger scale clinical fNIRS studies that can quantify the impact of psychedelics on the brain in standard clinical settings.
BibTeX
@misc{castillo2023acute,
  author = {Adelaida Castillo and Julien Dubois and Ryan M. Field and Frank A. Fishburn and Andrew Gundran and Wilson C. Ho and Sami Jawhar and Julian Kates‐Harbeck and Zahra M. Aghajan and Naomi Miller and Katherine L. Perdue and Jake Phillips and Wesley C. Ryan and Mahdi Shafiei and Felix Scholkmann and Moriah Taylor},
  title = {{Acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans: A TD-fNIRS neuroimaging study}},
  year = {2023},
  doi = {10.1101/2023.01.06.522912},
  howpublished = {bioRxiv},
}
Figure